Incyte-Merck test failure drives some cancer-fighter stocks way down
"The study test will be stopped," the firms said of its experimental immunosuppressant drug, epacadostat. The news drove related stocks down.
Shares of Incyte Corp., the Wilmington-based drug developer, fell 22.9 percent Friday, to $64.02 a share, after the company and Merck said a trial of Incyte's "powerful" immunosuppressant drug, epacadostat, combined with Merck's cancer-fighting drug Keytruda, failed to keep alive skin-cancer patients any longer than giving them plain Keytruda.
Incyte is one of the largest among a group of firms trying to develop cancer treatments based on the protein Indoleamine 2,3-dioxygenase (IDO2), which inhibits cell reproduction. Shares of another IDO-focused company, Iowa-based NewLinks Genetics, fell 42.6 percent to $4.20 per share. Incyte, which last year completed a new headquarters for hundreds of workers on the site of the former Wanamakers store near the US 202 exit from I-95, has other drug-development deals with Merck rival Bristol-Myers Squibb, Roche, and AstraZeneca.
"Based on these results," and the recommendations of the independent data-monitoring committee overseeing the tests, "the study will be stopped," the companies said in a joint statement. "While we are disappointed," analysis of the tests on metastatic melanoma patients — in a study dubbed Echo-301/Keynote-252 — "will contribute to our understanding" and future immunosuppressant therapies, Incyte chief medical officer Steven Stein said in a statement.
"We look forward to sharing the comprehensive data analysis from ECHO-301/KEYNOTE-252 with the scientific community at an upcoming medical meeting," added Merck Laboratories chief medical officer Roy Baynes.